TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE

标题：使用雄激素受体抑制剂阿帕鲁胺进行膀胱癌化学预防

• 批准号: 10677989
• 负责人: CHINTHALAPALLY RAO
• 金额: $ 104.61万
• 依托单位: UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-05 至 2024-08-04
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10677989
• 关键词: Androgen Receptor; Cause of Death; Chemopreventive Agent; Clinical Data; Drug Kinetics; FDA approved; Female; Link; Malignant neoplasm of urinary bladder; Modeling; Nitrosamines; Patients; Prevention strategy; Quality of life; Rattus; Recurrence; Research; Role; Signal Transduction; Travel; Urogenital Cancer; antagonist; cancer chemoprevention; improved; inhibitor; mortality; next generation; pre-clinical; predictive marker; prevent; tumor progression; urogenital tract

Bladder cancer (BC) is the second-most common cancer of the genitourinary tract and also the major cause of death in patients. Preventing BC is highly desirable to reduce recurrence, mortality and improve quality of life. Preclinical and clinical data indicate the potential role of AR signaling in different stages of BC. In view of the strong link between AR signals and bladder cancer progression, apalutamide, a FDA approved next-generation AR antagonist, could provide a preventive strategy in NMIBC to mitigate progression to MIBC. The overall objective of this task order is to determine the efficacy of Apalutamide against N-butyl-N(4-hydroxybutyl) nitrosamine (BBN) induced rat urinary bladder cancers. The task order will assess welldefined predictive biomarkers of bladder cancer inhibition by apalutamide.

膀胱癌（BC）是泌尿生殖道第二常见癌症，也是患者死亡的主要原因。预防乳腺癌对于减少复发、死亡率和提高生活质量非常重要。临床前和临床数据表明 AR 信号在 BC 不同阶段的潜在作用。鉴于 AR 信号与膀胱癌进展之间的密切联系，FDA 批准的下一代 AR 拮抗剂阿帕鲁胺可以为 NMIBC 提供预防策略，以减缓 MIBC 的进展。该任务顺序的总体目标是确定 Apalutamide 对 N-丁基-N(4-羟丁基)亚硝胺 (BBN) 诱导的大鼠膀胱癌的疗效。该任务顺序将评估阿帕鲁胺抑制膀胱癌的明确的预测生物标志物。